Physician profile
Amanda B Thomas
NPI 1326464769
$4,201.42
in general payments reported to CMS, 2019-2025
23 companies · $1,352 in 2025
The $1,352 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $502 · 2022: $572 · 2023: $834 · 2024: $941 · 2025: $1,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,074 · Education: $53.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,073.71 |
| Education | $53.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,092.06 | 2021-2025 | Fasenra, Airsupra, Breztri |
| Regeneron Healthcare Solutions, INC. | $769.91 | 2021-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $417.14 | 2021-2025 | Cuvitru, Takhzyro |
| Glaxosmithkline, LLC. | $373.97 | 2022-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Biocryst US Sales Co., LLC | $342.65 | 2022-2025 | Orladeyo |
| Genzyme Corporation | $206.82 | 2021-2025 | |
| Pharming Healthcare, INC. | $165.97 | 2021-2025 | Ruconest |
| Pfizer INC. | $134.17 | 2021-2025 | |
| Optinose US, INC. | $126.76 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $97.33 | 2024-2025 | |
| Amgen INC. | $90.04 | 2023-2025 | Tezspire |
| Abbvie INC. | $78.25 | 2021-2023 | |
| Csl Behring | $76.67 | 2022-2025 | Haegarda, Privigen, Hizentra |
| Genentech USA, INC. | $42.12 | 2024-2025 | Xolair |
| Blueprint Medicines Corporation | $39.55 | 2024 | Ayvakit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $30.73 | 2021-2024 | Xembify |
| Medtronic, INC. | $21.04 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.38 | 2021 | |
| Sun Pharmaceutical Industries INC. | $17.49 | 2021 | |
| Galderma Laboratories, L.P. | $17.39 | 2025 | Nemluvio |
| Tersera Therapeutics LLC | $14.63 | 2025 | Quzyttir |
| Cycle Pharmaceuticals INC | $14.29 | 2025 | Sajazir |
| Teva Pharmaceuticals USA, INC. | $14.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.